Saturday, October 3, 2026

USD/CNH Went Down By Over 2% In The Last 21 Sessions

ViaNews Editorial Team

December 4, 2023

USD/CNH Went Down By Over 2% In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 2.71% for the last 21 sessions. At 22:14 EST on Sunday, 3 December, USD/CNH (USDCNH) is $7.12.

USD/CNH's yearly highs and lows, it's 0% down from its 52-week low and 0% down from its 52-week high.

News about

  • Eur/usd: ECB dovish repricing not necessarily a damper – ING. According to FXStreet on Friday, 1 December, "However, that won't be necessary to put pressure on EUR/USD if short-term differentials reconnect with the pair.", "The 2-year EUR-USD swap spread is now at 178 bps the lowest since December 2022, when EUR/USD was at 1.05."
  • Eur/usd: December seasonals bullish – MUFG. According to FXStreet on Friday, 1 December, "Furthermore in 8 of the 11 occasions when EUR/USD moved higher in November it was followed by a December gain.", "Economists at MUFG Bank note that There is a seasonal bias that is quite compelling for EUR/USD in December."
  • Eur/usd: December 2023 - 01 December 2023. According to DailyForex on Friday, 1 December, "Speculative conditions in Forex including the EUR/USD have taken place as financial institutions have had their mid-term outlooks confirmed, this via inflation numbers from the U.", "The move of the EUR/USD upwards in November was remarkable considering the currency pair started the month near the 1.05200 ratio on the 1st. "
  • According to FXStreet on Friday, 1 December, "The main threats to our Dollar view are enduring US economic strength or another identity crisis in the Eurozone - recall EUR/USD failed to rally in 2001, despite the Fed cutting nearly 500 bps."

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com